Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort-Reference-Cited by-同舟云学术

Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort

Published:2024-06-18 Issue:9 Volume:29 Page:1311-1325
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Miyake Makito^ORCID,Nishimura Nobutaka,Oda Yuki,Miyamoto Tatsuki,Iida Kota,Inoue Kuniaki,Tachibana Akira,Yoshikawa Takanosuke,Sakamoto Keichi,Ohnishi Mikiko,Maesaka Fumisato,Takamatsu Norimi,Mieda Kosuke,Ohmori Chihiro,Matsubara Toshihiko,Tomizawa Mitsuru,Shimizu Takuto,Ohnishi Kenta,Hori Shunta,Morizawa Yosuke,Gotoh Daisuke,Nakai Yasushi,Torimoto Kazumasa,Tanaka Nobumichi,Fujimoto Kiyohide,

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02573-5.pdf

Reference23 articles.

1. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

2. Matsuda T, Okuyama A (2017) Incidence rate for bladder cancer in Japanese in Japan and in the United States from the cancer incidence in five continents. Jpn J Clin Oncol 47:284–285

3. Miyake M, Nishimura N, Oda Y et al (2024) Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort. Jpn J Clin Oncol 54:329–338

4. Barthelemy P, Loriot Y, Voog E et al (2023) Full analysis from AVENANCE: a real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC). J Clin Oncol. https://doi.org/10.1200/JCO.2023.41.6_suppl.471

5. Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383:1218–1230